Autonomic Nervous System Drugs Practice Questions

Q: All of the following drugs cause hypertensive crisis in patients with pheochromocytoma, EXCEPT:

Phenoxybenzamine. **Explanation:** In patients with **Pheochromocytoma**, the tumor secretes excessive amounts of catecholamines (epinephrine and norepinephrine). The management of these patients requires careful pharmacological handling to avoid a hypertensive crisis [1], [3]. **Why Phenoxybenzamine is the Correct Answer:** Phenoxybenzamine is a **non-selective, irreversible alpha-blocker**. It is the drug of choice for the preoperative management of pheochromocytoma because it blocks $\alpha_1$ and $\alpha_2$ receptors, preventing catecholamine-induced vasoconstriction [1]. Therefore, it **prevents** rather than causes a hypertensive crisis [2]. **Analysis of Incorrect Options:** * **Propranolol:** If a non-selective beta-blocker is given *before* adequate alpha-blockade, it leads to **unopposed alpha-mediated vasoconstriction** [2]. This causes a paradoxical, life-threatening rise in blood pressure (hypertensive crisis). * **Saralasin:** This is a partial agonist at Angiotensin II receptors. In high-renin states like pheochromocytoma, it can act as an agonist, stimulating the release of catecholamines from the tumor and triggering a crisis. * **Captopril:** While ACE inhibitors are generally safe, they can occasionally cause a profound, unpredictable drop in blood pressure followed by a reactive sympathetic surge, which may trigger a crisis in these patients. **High-Yield Clinical Pearls for NEET-PG:** 1. **Rule of 7-10:** In pheochromocytoma, alpha-blockade (Phenoxybenzamine) must be started **7 to 10 days before** beta-blockade to avoid a hypertensive crisis [1]. 2. **Metyrosine:** An adjuvant drug that inhibits *Tyrosine Hydroxylase* (the rate-limiting enzyme in catecholamine synthesis), used in malignant or inoperable cases [1]. 3. **Glucagon:** Contraindicated in pheochromocytoma as it directly stimulates the tumor to release catecholamines.

Q: Which antiglaucoma drugs are safe to use in a patient with asthma?

Betaxolol. The primary concern when using beta-blockers in patients with asthma is the risk of **bronchospasm**. This occurs due to the blockade of **β$_2$ receptors** in the bronchial smooth muscle, which normally mediate bronchodilation. **1. Why Betaxolol is the correct answer:** Betaxolol is a **cardioselective (β$_1$ selective)** adrenoceptor antagonist [1, 2]. Because it primarily targets β$_1$ receptors (found mainly in the heart) and has minimal affinity for β$_2$ receptors, it is significantly safer for the respiratory system [1]. While no beta-blocker is 100% safe in severe asthma, betaxolol is the preferred topical beta-blocker when such therapy is necessary for a patient with reactive airway disease [1]. **2. Why the other options are incorrect:** * **Timolol:** This is a **non-selective** beta-blocker (β$_1$ + β$_2$) [1]. Even when administered topically as eye drops, systemic absorption via the nasolacrimal duct can cause life-threatening bronchospasm in asthmatic patients. It is the most common antiglaucoma drug associated with this side effect [1]. * **Propranolol:** This is a prototypical non-selective beta-blocker [1]. It is not used topically for glaucoma and is strictly contraindicated in asthma due to its potent β$_2$ blocking effects [1]. **Clinical Pearls for NEET-PG:** * **Mechanism in Glaucoma:** Beta-blockers reduce intraocular pressure (IOP) by **decreasing the production of aqueous humor** from the ciliary body [1]. * **Systemic Absorption:** To minimize systemic side effects of eye drops, advise patients to perform **nasolacrimal occlusion** (pressing the inner corner of the eye) for 1-2 minutes after instillation. * **Other Safe Alternatives:** In asthmatics, if beta-blockers are risky, consider **Prostaglandin analogues** (Latanoprost) or **Carbonic anhydrase inhibitors** (Dorzolamide).

Q: All of the following conditions are contraindicated or likely to cause issues in a patient treated with Timolol maleate 0.5% eye drops for Primary Open Angle glaucoma, EXCEPT:

Hypertension. **Explanation:** Timolol maleate is a **non-selective beta-blocker** (blocking both $\beta_1$ and $\beta_2$ receptors). When administered topically as eye drops, it undergoes significant systemic absorption via the nasolacrimal duct, bypassing first-pass metabolism and potentially causing systemic side effects similar to oral beta-blockers. **Why Hypertension is the Correct Answer:** Beta-blockers are actually a standard class of drugs used to **treat** hypertension. Therefore, Timolol is not contraindicated in hypertensive patients; if anything, it may have a synergistic (though usually negligible) effect on lowering blood pressure. **Analysis of Incorrect Options:** * **Bronchial Asthma:** This is a **strict contraindication**. Blocking $\beta_2$ receptors in the lungs causes bronchoconstriction, which can precipitate a life-threatening asthma attack. * **Depression:** Beta-blockers are known to cross the blood-brain barrier and are associated with central nervous system side effects, including fatigue, lethargy, and worsening of clinical depression. * **Hypercholesterolemia:** Non-selective beta-blockers can adversely affect the lipid profile by decreasing HDL ("good" cholesterol) and increasing triglycerides. While not a total contraindication, it is a metabolic "issue" to monitor. **NEET-PG High-Yield Pearls:** * **Drug of Choice (DOC):** Prostaglandin analogues (e.g., Latanoprost) are the first-line treatment for POAG, but Timolol remains a frequently tested classic. * **Betaxolol:** If a patient has respiratory issues but requires a beta-blocker, **Betaxolol** (a cardioselective $\beta_1$ blocker) is the preferred alternative as it has less effect on pulmonary $\beta_2$ receptors. * **Cardiac Contraindications:** Avoid Timolol in patients with Bradycardia, 2nd or 3rd-degree Heart Block, or Overt Cardiac Failure.

Q: Which anti-adrenergic drug crosses the blood-brain barrier minimally?

Atenolol. **Explanation:**The ability of a drug to cross the blood-brain barrier (BBB) is primarily determined by its **lipophilicity** [2]. Beta-blockers are categorized based on their lipid solubility, which dictates their central nervous system (CNS) penetration and side-effect profile.**1. Why Atenolol is the Correct Answer:**Atenolol is a **highly hydrophilic (water-soluble)**, second-generation $eta_1$-selective blocker [2]. Due to its low lipid solubility, it crosses the BBB minimally [2]. This property makes it the preferred choice for patients who experience CNS side effects (like insomnia, vivid dreams, or depression) with other beta-blockers. It is primarily excreted unchanged by the kidneys [1].**2. Analysis of Incorrect Options:*** **Propranolol (Option A):** This is a highly **lipophilic** non-selective beta-blocker [2]. It crosses the BBB rapidly and extensively, which is why it is effective for migraine prophylaxis and performance anxiety, but frequently causes CNS side effects like sedation and nightmares [2].* **Oxprenolol (Option C) & Alprenolol (Option D):** Both are non-selective beta-blockers with **moderate to high lipophilicity**. They penetrate the CNS significantly more than atenolol [2].**3. High-Yield Clinical Pearls for NEET-PG:*** **Lipophilic Beta-blockers:** Propranolol, Metoprolol, Labetalol, Carvedilol (High CNS penetration) [2].* **Hydrophilic Beta-blockers:** Atenolol, Sotalol, Nadolol (Minimal CNS penetration) [2].* **Metabolism:** Lipophilic drugs are generally metabolized by the **liver** (shorter half-life), while hydrophilic drugs are excreted by the **kidneys** (longer half-life) [1].* **Clinical Choice:** Use Atenolol in patients with liver disease; use Propranolol/Metoprolol in patients with renal failure.

Q: Drug S is most like which of the following drugs?

Isoproterenol. ***Isoproterenol*** - Drug S demonstrates high **β1 and β2 adrenergic activity** with negligible **α-adrenergic activity**, which uniquely matches isoproterenol's receptor profile. - Isoproterenol is a **non-selective β-agonist** that produces **positive inotropic** and **chronotropic effects** (β1) along with **bronchodilation** and **vasodilation** (β2). *Epinephrine* - Has significant **α-adrenergic activity** in addition to β-activity, causing **vasoconstriction** at higher doses, unlike Drug S. - Shows a **mixed receptor profile** (α1/α2/β1/β2) with dose-dependent effects, contrasting with Drug S's pure β-selectivity. *Norepinephrine* - Primarily acts on **α1, α2, and β1 receptors** with minimal **β2 activity**, causing predominant **vasoconstriction**. - Lacks the significant **β2-mediated bronchodilation** and **vasodilation** profile seen in Drug S. *Phenylephrine* - Is a **selective α1-agonist** with no significant **β-adrenergic activity**, producing only **vasoconstriction**. - Completely lacks the **β1 and β2 receptor activation** that characterizes Drug S's pharmacological profile.

Q: Which of the following is the earliest and shortest acting skeletal muscle relaxant?

Suxamethonium. **Explanation:** **Suxamethonium (Succinylcholine)** is the correct answer because it is the only **depolarizing neuromuscular blocker** in clinical use. Its unique mechanism and metabolism account for its rapid profile: * **Earliest Onset:** It has the fastest onset of action (approx. 30–60 seconds) because it is a small, highly flexible molecule that rapidly reaches the motor endplate. * **Shortest Duration:** It has the shortest duration of action (approx. 5–10 minutes) because it is rapidly hydrolyzed by **pseudocholinesterase (plasma cholinesterase)** in the blood. **Analysis of Incorrect Options:** * **Rocuronium (Option A):** An aminosteroid non-depolarizing blocker. While it has the fastest onset among non-depolarizing agents (60–90 seconds), its duration is intermediate (30–40 minutes). * **Vecuronium (Option B):** An intermediate-acting non-depolarizing blocker with an onset of 2–3 minutes and a duration of 30–40 minutes. * **Atracurium (Option C):** An intermediate-acting benzylisoquinolinium agent. It is notable for **Hofmann elimination**, but its onset (2–3 minutes) and duration (20–35 minutes) are significantly longer than Suxamethonium. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Suxamethonium is the gold standard for **Rapid Sequence Induction (RSI)** due to its fast onset. * **Side Effects:** Watch for muscle fasciculations, hyperkalemia (avoid in burn/trauma patients), and it is a known trigger for **Malignant Hyperthermia**. * **Phase II Block:** Prolonged exposure to Suxamethonium can lead to a Phase II block, where the membrane repolarizes but becomes desensitized. * **Scumbeline Apnea:** Occurs in patients with genetic deficiency or atypical pseudocholinesterase.

Q: The action of non-competitive muscle blockers is affected by which of the following?

Hypocalcemia. **Explanation:** Non-competitive (depolarizing) muscle relaxants, such as **Succinylcholine**, act by mimicking acetylcholine at the nicotinic receptors, causing persistent depolarization of the motor endplate. **Why Hypocalcemia is the correct answer:** Calcium plays a critical role in neuromuscular transmission. Low extracellular calcium (**Hypocalcemia**) reduces the release of Acetylcholine (ACh) from the pre-synaptic nerve terminal. Since there is less endogenous ACh to compete for receptors or initiate normal contraction, the muscle becomes more sensitive to the effects of neuromuscular blockers. Clinically, hypocalcemia **potentiates** the blockade, leading to prolonged muscle relaxation and potential respiratory delay. **Analysis of Incorrect Options:** * **Hyponatremia:** While sodium is essential for action potential propagation, minor fluctuations in serum sodium levels do not significantly alter the clinical efficacy or duration of neuromuscular blockers compared to divalent cations like calcium and magnesium. * **Hyperthermia:** Generally, **hypothermia** (not hyperthermia) prolongs the duration of muscle blockers by slowing metabolism (e.g., pseudocholinesterase activity) and delaying organ excretion. Hyperthermia may actually shorten the duration of action for some agents. **High-Yield Clinical Pearls for NEET-PG:** * **Magnesium Interaction:** Hypermagnesemia (often seen in pre-eclampsia treatment) also potentiates neuromuscular blockers by inhibiting ACh release and decreasing post-junctional sensitivity. * **Hypokalemia:** Potentiates **non-depolarizing** blockers (e.g., Vecuronium) but can antagonize/resist **depolarizing** blockers (Succinylcholine). * **Phase II Block:** Succinylcholine can transition from a depolarizing to a non-depolarizing-like block (Phase II) with prolonged infusion or high doses.

Question 1

All of the following drugs cause hypertensive crisis in patients with pheochromocytoma, EXCEPT:

Accepted Answer

Phenoxybenzamine

Answer

Propranolol

Answer

Saralasin

Answer

Captopril

Question 2

Which antiglaucoma drugs are safe to use in a patient with asthma?

Accepted Answer

Betaxolol

Answer

Timolol

Answer

Propranolol

Answer

All the above

Question 3

All of the following conditions are contraindicated or likely to cause issues in a patient treated with Timolol maleate 0.5% eye drops for Primary Open Angle glaucoma, EXCEPT:

Accepted Answer

Hypertension

Answer

Hypercholesterolemia

Answer

Depression

Answer

Bronchial asthma

Question 4

Metoprolol is preferred over propranolol in some patients because it:

Accepted Answer

is less likely to cause bronchoconstriction

Answer

causes less cardiac depression

Answer

has both alpha- and beta-adrenoceptor blocking effects

Answer

is more effective as an antiarrhythmic

Question 5

Propranolol is useful in the treatment of all of the following EXCEPT:

Accepted Answer

Partial atrioventricular block

Answer

Angina

Answer

Idiopathic hypertrophic subaortic stenosis

Answer

Familial tremor

Question 6

Which anti-adrenergic drug crosses the blood-brain barrier minimally?

Accepted Answer

Atenolol

Answer

Propranolol

Answer

Oxprenolol

Answer

Alprenolol

Question 7

Drug S is most like which of the following drugs?

Accepted Answer

Isoproterenol

Answer

Epinephrine

Answer

Norepinephrine

Answer

Phenylephrine

Question 8

Which of the following is the earliest and shortest acting skeletal muscle relaxant?

Accepted Answer

Suxamethonium

Answer

Rocuronium

Answer

Vecuronium

Answer

Atracurium

Question 9

The action of non-competitive muscle blockers is affected by which of the following?

Accepted Answer

Hypocalcemia

Answer

Hyponatremia

Answer

Hyperthermia

Answer

All of the above

Question 10

Use of Ergotamine is contraindicated in which of the following conditions?

Accepted Answer

Ischaemic heart disease

Answer

Diabetes mellitus

Answer

Anemia

Answer

Postpartum hemorrhage

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?